Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland

被引：0
|
作者：
Michaela Barbier
Nicholas Durno
Craig Bennison
Mathias Örtli
Christian Knapp
Matthias Schwenkglenks
机构：
[1] University of Basel,Institute of Pharmaceutical Medicine (ECPM)
[2] OPEN Health,undefined
[3] AbbVie AG,undefined
来源：
The European Journal of Health Economics | 2022年 / 23卷
关键词：
Rituximab; Venetoclax; Chronic lymphocytic leukemia; Cost-effectiveness; Partitioned survival model; EVPI; 119;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：837 / 846
页数：9
相关论文
共 50 条
  • [31] Venetoclax Management and care for patients with relapsed or refractory chronic lymphocytic leukemia
    Paradis, Heather Brumbaugh
    Alter, Debbie
    Lterandi, Diane
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (05) : 604 - 610
  • [32] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Freise, Kevin J.
    Jones, Aksana K.
    Eckert, Doerthe
    Mensing, Sven
    Wong, Shekman L.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 515 - 523
  • [33] Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Kevin J. Freise
    Aksana K. Jones
    Doerthe Eckert
    Sven Mensing
    Shekman L. Wong
    Rod A. Humerickhouse
    Walid M. Awni
    Ahmed Hamed Salem
    Clinical Pharmacokinetics, 2017, 56 : 515 - 523
  • [34] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB USE IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE
    Mandrik, O.
    Zalis'ka, O.
    Severens, J. L.
    VALUE IN HEALTH, 2012, 15 (04) : A221 - A221
  • [35] BUDGET IMPACT OF ZANUBRUTINIB FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Xiao, Y.
    Gani, R.
    Xue, M.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (12) : S65 - S66
  • [36] The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia
    Vitale, Candida
    Ferrajoli, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (08) : 885 - 894
  • [37] Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Smolej, Lukas
    Doubek, Michael
    Panovska, Anna
    Simkovic, Martin
    Brychtova, Yvona
    Belada, David
    Motyckova, Monika
    Mayer, Jiri
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1278 - 1282
  • [38] Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia
    Felipe Casado, Luis
    Angel Hernandez, Jose
    Jarque, Isidro
    Echave, Maria
    Angel Casado, Miguel
    Castro, Antonio
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (03) : 264 - 272
  • [39] Venetoclax and rituximab, a promising association in the treatment of chronic refractory or relapsed lymphoid leukemia
    Bobin, Arthur
    Dreyfus, Brigitte
    Tomowiak, Cecile
    HEMATOLOGIE, 2018, 24 (03): : 204 - 206
  • [40] Venetoclax-Rituximab in Chronic Lymphocytic Leukemia
    Copur, Mehmet S.
    Gauchan, Dron
    Crockett, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2142 - +
12345